Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeCalCU: Beclometasone dipropionate effect on faecal calprotectin in ulcerative colitis remission
2017-000330-61Phase 3Active
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Beclometasone dipropionate with Placebo (2 arms). Primary endpoint: Faecal calprotectin <100 µg/g at week 4. Started Apr 2017; status: active.
02
Drugs
beclomethasone dipropionate
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-000330-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000330-61.